Silence Therapeutics GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
0
Ending by 2030
Apr 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 12, 2027The maintenance fee for Nucleic acids for inhibiting expression of C3 in a cell (US 11,753,642) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Nucleic acids for inhibiting expression of PROS1 in a cell (US 11,820,971) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Nucleic Acids for Inhibiting Expression of a Target Gene Comprising Phosphorodithioate Linkages (US 11,873,489) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Nucleic acid linked to a trivalent glycoconjugate (US 11,912,993) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 13 US 12,760,306 siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,913,945 | Nucleic acid linked to a trivalent glycoconjugate In force · USPTO record | In force | USPTO record | |
| US 11,912,993 | Nucleic acid linked to a trivalent glycoconjugate In force · USPTO record | In force | USPTO record | |
| US 11,015,198 | Products and Compositions In force · High confidence | In force | High confidence | |
| US 11,414,660 | Products and compositions In force · USPTO record | In force | USPTO record | |
| US 11,987,794 | Products and compositions In force · USPTO record | In force | USPTO record | |
| US 11,174,483 | Products and Compositions In force · High confidence | In force | High confidence | |
| US 11,319,537 | Nucleic Acids for Inhibiting Expression of Lpa in a Cell In force · High confidence | In force | High confidence | |
| US 12,054,717 | Nucleic Acids for Inhibiting Expression of Lpa in a Cell In force · High confidence | In force | High confidence | |
| US 12,084,656 | Products and Compositions In force · Low confidence | In force | Low confidence | |
| US 11,560,563 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND In force · High confidence | In force | High confidence |
Also on record, not counted in the 16: 19 lapsed for an unpaid fee · 15 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 1 abandoned · 16 no status recorded